AGENO, WALTER
 Distribuzione geografica
Continente #
NA - Nord America 43.677
EU - Europa 22.199
AS - Asia 5.774
Continente sconosciuto - Info sul continente non disponibili 55
SA - Sud America 38
OC - Oceania 23
AF - Africa 12
Totale 71.778
Nazione #
US - Stati Uniti d'America 43.629
IT - Italia 11.506
UA - Ucraina 4.067
TR - Turchia 2.780
SE - Svezia 1.797
DE - Germania 1.521
VN - Vietnam 1.398
IE - Irlanda 1.229
CN - Cina 1.002
FI - Finlandia 735
GB - Regno Unito 700
SG - Singapore 442
FR - Francia 276
RU - Federazione Russa 154
IN - India 66
EU - Europa 53
CA - Canada 43
BE - Belgio 40
NL - Olanda 38
JP - Giappone 37
CZ - Repubblica Ceca 33
AU - Australia 18
BR - Brasile 18
ES - Italia 16
CH - Svizzera 13
PT - Portogallo 13
CL - Cile 10
RO - Romania 9
HK - Hong Kong 8
PL - Polonia 8
EG - Egitto 7
IR - Iran 7
MY - Malesia 7
AT - Austria 6
DK - Danimarca 6
IL - Israele 6
AR - Argentina 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
GR - Grecia 4
LK - Sri Lanka 4
MK - Macedonia 4
BG - Bulgaria 3
CO - Colombia 3
MX - Messico 3
TW - Taiwan 3
AL - Albania 2
EE - Estonia 2
HR - Croazia 2
ID - Indonesia 2
IQ - Iraq 2
KW - Kuwait 2
KZ - Kazakistan 2
LI - Liechtenstein 2
NG - Nigeria 2
NO - Norvegia 2
SI - Slovenia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
DZ - Algeria 1
KE - Kenya 1
KR - Corea 1
MD - Moldavia 1
MM - Myanmar 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PR - Porto Rico 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
Totale 71.778
Città #
Milan 8.476
Fairfield 7.198
Woodbridge 4.799
Houston 3.518
Ashburn 3.510
Jacksonville 3.301
Seattle 2.793
Wilmington 2.600
Cambridge 2.459
Ann Arbor 2.425
Chandler 2.236
Izmir 1.393
Princeton 1.350
Dublin 1.221
Dearborn 961
Boardman 807
Dong Ket 683
Nyköping 664
Rome 620
Singapore 422
San Diego 398
San Mateo 308
Ogden 261
Chicago 218
Como 188
Washington 164
Beijing 159
London 140
Düsseldorf 137
Hefei 124
Redmond 122
Santa Clara 119
Nanjing 95
Kocaeli 88
New York 86
Kunming 81
Verona 80
Norwalk 75
Los Angeles 59
Nanchang 56
Jinan 50
Helsinki 46
Dallas 45
Guangzhou 42
Munich 42
Kilburn 39
Falls Church 38
Besana In Brianza 33
Brussels 33
Tokyo 32
Philadelphia 30
Fuzhou 29
Brno 28
Prescot 27
Redwood City 26
Chiswick 25
Frankfurt am Main 25
Toronto 23
Berlin 22
Shenyang 22
Acton 20
New Bedfont 20
Zhengzhou 20
Phoenix 19
Ponte Lambro 19
Detroit 18
Wandsworth 18
Hounslow 17
Pune 15
Wuhan 15
Xian 15
Islington 14
Southwark 14
São Paulo 14
Changsha 13
Chengdu 13
Indiana 13
Lappeenranta 13
San Francisco 13
Auburn Hills 12
Hebei 12
Andover 11
Bologna 11
Ningbo 11
Quzhou 11
Saint Petersburg 11
Shaoxing 11
Chongqing 10
Busto Arsizio 9
Shanghai 9
Stockholm 9
Suresnes 9
Bangalore 8
Baotou 8
Florence 8
Madrid 8
Paris 8
Ralingen 8
Hangzhou 7
Hanoi 7
Totale 55.552
Nome #
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 262
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 243
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 226
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 224
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 220
Risk of recurrence of unusual site venous thromboembolism 213
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 203
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 200
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 197
Abdominal obesity and the risk of recurrent deep vein thrombosis 195
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 194
Breadth of complications of long-term oral anticoagulant care 193
Optimal treatment duration of venous thrombosis 190
Management of recurrent venous thromboembolism in cancer patients 190
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 189
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 188
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 188
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 186
Patient selection for thromboprophylaxis in medical inpatients 186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 185
Exaggerated initial response to warfarin following heart valve replacement 183
Prevention and treatment of venous thromboembolism 183
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 183
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 181
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 180
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 179
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 179
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 179
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 178
Venous ischemic syndromes 178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 176
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 176
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 175
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 175
Management of incidental splanchnic vein thrombosis in cancer patients 174
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 174
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 171
Warfarin interactions with antibiotics in the ambulatory care setting 171
Treating patients with cancer and acute venous thromboembolism 171
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 171
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 171
Duration of anticoagulation after venous thromboembolism in real world clinical practice 170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 170
Managing challenging patients with venous thromboembolism: A practical, case-based approach 170
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 169
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 169
Venous and arterial thrombosis in patients with HIV infection 168
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 168
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 168
Update on the diagnosis and management of pulmonary embolism 168
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 167
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 167
Direct oral anticoagulants in rare venous thrombosis 167
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 167
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis 166
Oral rivaroxaban for symptomatic venous thromboembolism 164
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. 164
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH 164
Applying EBM in clinical practice 163
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 163
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 163
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 163
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 163
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation. 163
Statins and secondary prevention of ischemic and hemorrhagic stroke 162
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 162
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature 161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 160
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding 160
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 160
ABO blood group and vascular disease: an update 160
Spotlight on real-world evidence for the treatment of DVT: XALIA 160
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 159
Dabigatran in clinical practice: Contemporary overview of the evidence 158
Low-molecular -weight heparin in pregnancies after ART -A retrospective study- 158
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial 158
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies 157
Guidance for the management of venous thrombosis in unusual sites 157
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide 157
Venous thromboembolism: Past, present and future 157
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 156
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. 156
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 156
Is diabetes a hypercoagulable state? A critical appraisal 156
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. 155
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 155
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation 155
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 155
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs 155
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 154
Prevention of in-hospital VTE: why can't we do better? 153
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events 153
Extended oral anticoagulant therapy after a first episode of pulmonary embolism 152
How I treat splanchnic vein thrombosis 152
The role of thrombolytic therapy in pulmonary embolism 152
Statins for acute ischemic stroke 152
Totale 17.341
Categoria #
all - tutte 287.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 287.799


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012.537 0 0 0 2.942 986 1.555 2.116 1.734 1.148 917 259 880
2020/202113.656 231 1.104 1.560 1.768 972 1.396 543 1.226 1.503 803 953 1.597
2021/20226.828 757 872 355 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20252.043 69 75 1.781 118 0 0 0 0 0 0 0 0
Totale 72.644